Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20262444 Fuzheng Tonglin Pills Prostatic Hyperplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262444 clinical trial report covering Fuzheng Tonglin Pills, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684144 Maridebart Cafraglutide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684144 clinical trial report covering Maridebart Cafraglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684235 Maridebart Cafraglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684235 clinical trial report covering Maridebart Cafraglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07685808 Olatorepatide Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07685808 clinical trial report covering Olatorepatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684040 Adebrelimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684040 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684456 Utidelone HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684456 clinical trial report covering Utidelone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684287 Sirolimus Albumin-Bound Epithelioid Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684287 clinical trial report covering Sirolimus Albumin-Bound, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07683026 Golimumab Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07683026 clinical trial report covering Golimumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07683806 Roflumilast Dermatitis, Seborrheic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07683806 clinical trial report covering Roflumilast, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684170 CTX-471 Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684170 clinical trial report covering CTX-471, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07684599 Mocertatug Rezetecan MSS/pMMR/MSI-L Endometrial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07684599 clinical trial report covering Mocertatug Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07683754 Trastuzumab--ANNS(Synthon BV) Metastatic human epidermal growth factor 2 positive carcinoma of breast Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07683754 clinical trial report covering Trastuzumab--ANNS(Synthon BV), Phase 3, endpoints, sponsor, geography, readout timing and development white space.